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To study the economic implications of epilepsy in Hong Kong, a cost-of-illness study was performed on a retrospective cohort
of medically treated patients from a regional hospital. A societal perspective was examined. Utilization data from 1992 to 1996
were reviewed to obtain the direct costs. Lost productivity was used as a proxy for estimating the indirect costs. Future cost
projected over 10 years was derived by incorporating model parameters. Of 745 records reviewed, total direct costs added up
to USD 0.98 million and indirect costs to USD 1.32 million. Regarding the overall direct costs, hospitalization was the most
consumptive item among patients with a shorter history of epilepsy and those with suboptimal seizure control. The mean total
cost per patient increased steadily from 1992 to 1996 except for those with long-standing remission, and was highest in patients
with medically refractory epilepsy in terms of both the actual value and rate of increment. Parameters with the most leverage
on future cost would be unemployment rate and annual discount rate. The overall economy of the society would exert a major
effect on the future cost of epilepsy, in particular, for patients with poorly controlled disease.
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The International League Against Epilepsy Commis-
sion on Economic Aspects of Epilepsy (ICEE) was
founded following the 20th International Epilepsy
Congress, at which the socioeconomic issues of
epilepsy from various nations were addressed1. The
report of the ICEE workshop, published in 1996,
highlighted the importance of economic impacts from
epilepsy and research into this area2. The scarcity
of health-care resources has also encouraged the ap-
praisal of economic consequences from various health
problems and services. Socioeconomic impacts of
epilepsy3–7 and the treatment options8, 9 have been
intensively studied in many Western countries, but
data from Hong Kong and China are still lack-
ing.
The incidence and prevalence of epilepsy in ur-
ban China is 35 per 100 000 per annum and 4.4 per
1000, respectively10. The population of Hong Kong is
6.5 million. We estimate that 28 600 people are suf-
fering from epilepsy and the number of new cases1059–1311/99/080456 + 09 $12.00/0per year is 2300. Our unit provides acute admissions
and secondary care for adult epileptic patients from
the Central, Western, and Southern districts of Hong
Kong Island, which consists of an urban population
of approximately 0.5 million. We offer open access to
the general public and services are largely free at the
point of delivery. From our recent service data (un-
published), demands for both inpatient and outpatient
services in epilepsy are growing by about 10% per
year. In 1996, there were about 500 episodes of admis-
sions and 3000 outpatient consultations for epilepsy,
which accounted for approximately one-third of the
overall neurology service. Expenditure on antiepilep-
tic drugs (AEDs) has almost doubled over the 3 years
from 1994 to 1996. However, epilepsy surgery is still
being under-utilized with only 15 surgical procedures
performed between 1994 and 1996.
The purpose of this study is to explore and elucidate
the socioeconomic weights of epilepsy that are of local
relevance.c© 1999 BEA Trading Ltd
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A retrospective cost-of-illness study from a cohort
of adult patients followed up at the Epilepsy Clinic
and under medical treatment in 1996 was performed.
Excluded from the analysis were patients: (1) with
a single seizure and not on AEDs; (2) in remission
not requiring AEDs; (3) who had undergone epilepsy
surgery; (4) with psychogenic seizures or uncertain di-
agnosis of epilepsy; (5) with less than 1 year of follow-
up by the end of 1996; and (6) in AED trials. Utiliza-
tion data from 1992 to 1996 of the target population
were collected from their clinical records. The initial
valuation of cost items was in Hong Kong currency,
which is constantly pegged to that of the United States
at a rate of HKD 7.75 to USD 1.0.
The patients were divided into five prognostic
groups according to their seizure frequency, treatment
response, and natural history of illness (Table 1). Pa-
tients with initial suboptimal seizure control but who
later achieved remission with conventional AEDs, i.e.
phenytoin, carbamazepine, valproic acid, phenobar-
bitone, primidone, and benzodiazepines, were allo-
cated into either Group 1 or 2. Patients with medically
refractory epilepsy (MRE) given adjunctive AEDs,
i.e. vigabatrin, gabapentin, and lamotrigine, and who
achieved intermediate seizure control or remission
were still classified as Group 4. For patients who were
seizure free for 2 to 3 years, AEDs would be gradually
discontinued if this was socially and psychologically
acceptable to them.
Avoidable costs attributable to epilepsy in Groups 1
to 4 were estimated from a societal perspective. For
Group 5 patients, epilepsy was an associated disorder
and the majority of avoidable expenditures were due
to their primary neurological disorders.
Direct costs
Direct costs are the resources directly related to the
organization and provision of services. The net direct
costs were estimated by synthesizing secondary and
model data, which included expenditures on: (1) hos-
pitalization; (2) outpatient service; (3) AEDs; and
(4) therapeutic drug monitoring (TDM) at the clinic.
Our hospital was under contract terms with the Hos-
pital Authority (HA) so that a fixed sum of monetary
subsidy per patient would be paid for each day of hos-
pitalization regardless of the amount of resources util-
ized in that particular admission. In addition, the pa-
tients had to pay a fixed fee of about 5% of the sub-
sidy. The cost of each admission was calculated as the
product of the number of days of inpatient care and
the amount of subsidy plus the patient’s payment at the
time of hospitalization. Only the admissions for acutemanagement of epilepsy or complications arising from
epileptic seizures or its treatment were costed. Admis-
sions for epilepsy surgery or pre-surgical evaluations
were not included. The cost of TDM was estimated
similarly. The hospital was paid a fixed subsidy for
each TDM test performed. The total cost of TDM for
each patient was calculated as the product of the num-
ber of tests carried out and the amount of subsidy at the
time of testing. TDM would be performed when poor
drug compliance or AED toxicity was suspected, fol-
lowing a breakthrough seizure, during pregnancy, and
in difficult cases to determine the optimal dosage of
AEDs. TDM was not performed routinely on patients
with good seizure control without clinical evidence of
AED toxicity.
A shadow market price was used to reflect the cost
of outpatient service. The fees for neurology consul-
tation from specialist clinics attached to private hospi-
tals were obtained through a survey and a mean value
was calculated. A 20% capacity cost and 30% cost-to-
charge difference (i.e. profit) were deducted from this
value to give the cost of each visit to our outpatient
clinic.
The hospital dispensary provided all the AEDs at no
additional charge to the patients. To estimate the ex-
penditure on AEDs, each record was reviewed man-
ually to obtain the amount of drugs prescribed from
1992 to 1996 inclusively. Drug costs were calculated
as the product of the number of tablets prescribed and
the purchasing price of each tablet at the time of pre-
scription.
The cost for investigations was not included. Work-
up for new patients, including blood tests, computer-
ized tomography scan, and electroencephalogy, were
usually performed during the initial admission so
that their costs could be absorbed into that of hospi-
talization. Expenses on pre-surgical evaluation, such
as magnetic resonance imaging, single photon emis-
sion computed tomography scan, video-telemetry, and
intra-arterial amobarbital test were also not included
since the analysis was restricted to the cost informa-
tion from medically treated patients.
Indirect costs
Indirect costs are related to the consequences of the
illness rather than to the specific delivery of med-
ical care. All indirect expenditures were valued at
their opportunity costs, and lost productivity was used
as a proxy for estimating opportunity costs. There
were two sources of lost productivity from epilepsy—
morbidity and mortality. The former would result in
partial loss of productivity while the latter in total loss.
The estimation of indirect costs was based on a prog-
nostic model in which corresponding group-specific
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Table 1: (Left) Prognostic groups of the target population. (Right) Excessive unemployment rates and excessive mortality (age
and sex specific) attributable to epilepsy, and their duration after onset of illness for prognostic Groups 1 to 4.
Unemployment and mortality in excess of the national rate
Unemployment Duration Mortality Duration
Group 1 Patients in remission, <7 years history of epilepsy 2× 2 years none —
— ‘Early remission’
Group 2 Patients in remission, long-standing history 2× 4 years none —
— ‘Long-term remission’
Group 3 Patients with intermediate seizure control 2.5× lifetime 1.2× 10 years
Group 4 Medically refractory epilepsy with >1 seizure/month 4× lifetime 4× lifetime
Group 5 Patients disabled from neurological diseases other than chronic epilepsy or had major developmental abnormalitiesmortality rates and lost productivity were defined3 (Ta-
ble 1). (Begley et al.3 included in their model a sixth
prognostic group—patients with difficult seizure con-
trol initially but later achieved remission. Because of
the retrospective nature of the present study, they could
be allocated into either Group 1 or 2, and were not
classified separately.) The age- and sex-specific life
expectancy, unemployment rate, and median annual
income of the Hong Kong population from 1992 to
1996 were incorporated into this model. The cost of
lost productivity during the study period for each pa-
tient per year was obtained by multiplying the product
of the overall population unemployment rate and the
group-specific excessive unemployment with the me-
dian annual income of the corresponding year.
Estimating the future costs
Future costs were estimated by incorporating model
data. Estimation was restricted to a projected period of
10 years to avoid significant deviations from the model
parameters and assumptions, even though epilepsy
may be a life-long disease. The rate of inflation in
direct costs was deduced from the mean composite
consumer price index (CCPI) of Hong Kong from
1992 to 1996, which was 8.5% per year. The mean
increment rate in median income and unemployment
rate from the same period, which were 8.7% per year
and 2.5%, respectively, were applied in deducing the
indirect costs. Time preference was adjusted with an
annual discount rate of 4%. The natural history of
epilepsy and likelihood of AED withdrawal in Group 1
patients were predicted from the results of the Medi-
cal Research Council Antiepileptic Drug Withdrawal
Study11 (Appendix 1). Declining exponential approxi-
mation was applied to determine the length of survival
for each patient12, 13. The mortality rate of each patient
was the product of the reciprocal of the correspond-
ing average age- and sex-adjusted life expectancy of
the whole population and his/her group-specific exces-
sive mortality. The reciprocal of that figure would be
his/her approximate length of survival. The total pro-jected costs for each patient would be the cumulative
sum over 5 or 10 years of the direct costs for the ex-
pected duration of requiring medical treatment and the
indirect costs for the expected duration with produc-
tivity loses. Indirect costs from mortality would be in-
cluded if premature death was expected within the pro-
jected time frame. Direct costs would be absent after
death.
Univariate sensitivity analyses to allow for par-
ameter uncertainties were performed. The variables
and their ranges used for analysis were as follows:
(1) CCPI: 6.3 to 9.6%; (2) unemployment rate: 1.9 to
3.5%; (3) annual increment rate of the median income:
6.4 to 10.2%; (4) annual discount rate: 0 to 8%14; and
(5) the lower to upper end of the 95% confidence in-
terval of the mean total costs at 1996. The ranges of
the first three variables were derived from their corre-
sponding minimal and maximal figures between 1992
and 1996.
RESULTS
Of the 745 patients reviewed, 388 patients (52.0%)
were in remission while on AEDs, in whom
302 (40.5%) were in long-term remission and
86 (11.5%) were in early remission, 92 (12.4%) had
MRE, and 186 (25.0%) were in the intermediate
group. The remaining 79 patients (10.6%) belonged to
the last group with disabling neurological diseases or
major degree of developmental abnormalities.
Overall costs from 1992 to 1996
From 1992 to 1996, the overall direct costs of all
groups added up to USD 0.98 M and indirect costs
to USD 1.32 M. Direct and indirect costs accounted
for 42.7% and 57.3% of the total expenditure, respec-
tively (Table 2). The total indirect costs were higher
than direct costs in all prognostic groups except for
those in long-term remission.
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Table 2: Total direct and indirect costs, in thousands of USD, and proportions of direct and indirect costs in the overall expenditure
for prognostic Groups 1 to 4 and all four groups from 1992 to 1996.
All groups Group 1 Group 2 Group 3 Group 4
Total direct costs 92–96 982.8 84.6 285.8 317.1 295.3
Total indirect costs 92–96 1320.7 121.7 18.3 685.6 495.1
Direct : Indirect costs 42.7 : 57.3 41.0 : 59.0 94.0 : 6.0 31.6 : 68.4 37.4 : 62.6Regarding the direct costs of all the groups,
23.8% of the overall amount was spent on drugs,
39.0% on outpatient service, 35.3% on hospitalization,
and 1.9% on TDM. This proportion for each prog-
nostic group is summarized in Table 3. For patients
in remission (Groups 1 and 2), the overall AED cost
was less than 20% of the total direct costs. These pa-
tients also required admission for the following rea-
sons: (1) seizures related to poor drug compliance,
(2) seizures due to suboptimal AED treatment, and
(3) withdrawal seizures. The overall expenditure in
hospitalization for patients with early disease was al-
most double that of those with long-standing epilepsy.
On the other hand, over half of the total direct costs
were used to cover outpatient expenses of patients in
long-term remission. For patients with MRE and inter-
mediate seizure control (Groups 3 and 4), a higher pro-
portion of the total direct costs was spent on drugs, in
particular, patients with MRE in whom overall AED
cost was almost 10% higher than that for the other
groups. However, hospitalization was still the most
consumptive item among these patients, as well as for
those in early remission.
Average annual costs
The mean total cost per patient with MRE, intermedi-
ate seizure control, early remission, and long-term re-
mission were USD 1.30 K, 0.77 K, 0.45 K, and 0.24 K
in 1992, and 2.60 K, 1.56 K, 0.80 K, and 0.23 K in
1996, respectively. The values between 1992 and 1996
are shown in Fig. 1. The mean total cost per patient,
except those in long-term remission, increased steadily
from 1992 to 1996. (The peak in 1995 was due to high
indirect costs from an unemployment rate of 3.5%.)
The rate of increase in mean total cost per patient was
different for each group and was highest for patients
with MRE, but remained almost unchanged for those
in long-term remission.
To account for the differential increments of mean
total cost in various prognostic groups, an analysis of
the breakdown of cost items and their trends was car-
ried out. The respective mean cost per person for hos-
pitalization, outpatient visit, AEDs, and indirect costs
for patients with MRE were USD 0.15 K, 0.14 K,
0.13 K, and 0.86 K in 1992, and 0.23 K, 0.24 K,0.36 K, and 1.76 K in 1996, respectively. The mean
AED cost and indirect costs per person for those
with intermediate seizure control also increased from
USD 0.06 K and 0.55 K, to 0.12 K and 1.10 K, re-
spectively. The respective mean costs per person on
hospitalization, outpatient visit, and AEDs for patients
in early remission were USD 0.10 K, 0.13 K, and
0.02 K in 1992, and 0.11 K, 0.14 K, and 0.06 K in
1996, while those for patients in long-term remission
remained similar throughout the period.
Future costs, 1997 to 2006
The projected total costs (adjusted to the 1996 value)
per patient with MRE, intermediate seizure control,
early remission, and long-term remission over 5 and
10 years would be USD 13.64 K and 40.04 K, 8.05 K
and 18.00 K, 1.73 K and 3.39 K, and 1.31 K and
2.93 K, respectively (Fig. 2).
Results of sensitivity analyses are summarized in
Table 4. Variations of future projected costs were
largest for patients with MRE and least for those in
remission. Parameters with the most leverage on pro-
jected costs, in particular, for patients with MRE, were
unemployment rate and annual discount rate.
DISCUSSION
The present report is one of the very few economic
studies on epilepsy performed in Southeast Asia and
the first in a Chinese population. Indirect costs ac-
counted for about 60% of the total resource consump-
tion. Regarding the overall direct costs, hospitaliza-
tion was the most consumptive item in patients with
a shorter history and those with suboptimal seizure
control. The mean total cost per patient, except for
those with long-standing remission, increased steadily
from 1992 to 1996, and was highest for patients with
MRE in terms of both the actual value and rate of in-
crement. Parameters with the highest impact on future
cost would be unemployment rate and annual discount
rate, in particular, for patients with poorly controlled
disease.
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Table 3: Breakdown of items in direct costs, in thousands of USD, and percentage of total direct costs for prognostic Groups 1 to
4 and all four groups from 1992 to 1996.
Cost of: Hospitalization Outpatient AED TDM
All groups 347.0 382.9 233.9 18.9
Proportion of total direct cost 35.3% 39.0% 23.8% 1.9%
Group 1 36.2 33.8 12.7 1.9
42.8% 40.0% 15.0% 2.2%
Group 2 69.4 160.2 55.4 0.9
24.3% 56.0% 19.4% 0.3%
Group 3 120.7 113.3 70.6 12.5
38.1% 35.7% 22.3% 3.9%
Group 4 120.8 75.7 95.2 3.7
40.9% 25.6% 32.2% 1.3%
(AED, antiepileptic drug; TDM, therapeutic drug monitoring.)
1992
0.0K
0.5K
1.0K
1.5K
2.0K
2.5K
3.0K
3.5KSD
1993 1994 1995 1996
2.6
3.0
1.9
1.8
1.3
0.8
0.5
0.2
0.9
0.8
0.2
1.1
0.9
0.2
1.7
1.1
0.2
1.6
0.8
0.2
Fig. 1: Mean total cost, in thousands of USD, per patient per year for prognostic Groups 1 to 4 from 1992 to 1996. (——, Group 1;
— —, Group 2; —N—, Group 3; —•—, Group 4.)
5
years
Group 1
0
5000
10000
15000
20000
25000
30000
35000 Indirect costs
Direct costs
40000
45000SD
Group 2 Group 3 Group 4 10
years
Group 1 Group 2 Group 3 Group 4
Fig. 2: Direct and indirect components of the projected costs, in USD, of each prognostic group over 5 and 10 years. (2, Indirect
costs; , direct costs.)
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Table 4: Univariate sensitivity analyses of the projected costs, in thousands of USD, over 5 and 10 years of each prognostic group
(adjusted to the 1996 value).
Projected total cost over: 5 years 10 years
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4
Baseline 1.73 1.31 8.05 13.64 3.39 2.93 18.00 40.04
CCPI 6.3% 1.65 1.23 7.89 13.35 3.05 2.60 17.34 38.08
9.6% 1.78 1.35 8.13 13.79 3.58 3.11 18.36 40.64
Unemployment rate 1.9% 1.66 1.31 6.75 11.57 3.32 2.93 15.10 37.28
3.5% 1.86 1.31 10.2 17.09 3.52 2.93 22.83 48.93
Income increment/year 6.4% 1.73 1.31 7.71 13.09 3.38 2.93 16.65 37.63
10.4% 1.74 1.31 8.32 14.08 3.40 2.93 19.23 45.19
Annual discount rate 8% 1.57 1.17 7.17 12.15 2.79 2.36 14.56 31.42
0% 1.93 1.48 9.09 15.43 4.21 3.71 22.87 52.36
95% CI of mean lower 1.41 1.15 7.51 12.74 2.68 2.57 16.79 38.14
upper 2.07 1.47 8.60 14.54 4.10 3.30 19.25 41.94
(CCPI, composite consumer price index; CI, confidence interval.)Selection of the target population
The target population of the present analysis was se-
lected from a hospital-based clinic rather than from a
primary care population. In Hong Kong, 70% of pri-
mary care is provided by private sector physicians on
a free-for-service basis, while the HA provides over
90% of specialist care15, which is almost fully subsi-
dized so that patients’ out-of-pocket payment is min-
imal. Shared care of epilepsy between specialists and
primary care physicians is not properly structured, and
epileptic patients can rarely afford private health-care
because of the chronicity of their illness and inade-
quate insurance cover. Unlike the United Kingdom16
and United States17 where primary care physicians
have a major role in epilepsy management, patients
in Hong Kong are almost solely cared for by hospital
clinics even for non-refractory cases. Because of this
unusual setting, data of the present study incorporated
both community- and hospital-based populations. This
also explains why a large number of our patients were
in remission.
The target population was categorized into five
prognostic groups according to their disease severity
and response to treatment, which would determine an
individual’s cost-of-illness (COI). This group-specific
effect on resource consumption was also expressed by
some3, 18 but not all studies5, 7. Nevertheless, consid-
erable heterogeneity may still exist within individual
prognostic groups, in particular, Group 3.
Approach in valuing inputs
When real data are inadequate or absent, the use of
consumption models is accepted as a valid, and of-
ten necessary, form of scientific inquiry for economic
analyses19. However, their use is often subjected to
controversies since information applied for makinginferences are derived from diverse sources of vary-
ing qualities. The ICEE report stated that there is no
consensus on a universally applicable method of eco-
nomic study in epilepsy2. A few consumption models
can be used for deriving inputs in the evaluation of
economic burden and cost effectiveness of interven-
tional options. The most widely used approach is by
gross costing (assigning an average value to each pa-
tient for a particular event) on model data3, 4, 6–9, 20, 21.
Other less commonly applied methods include micro-
costing (directly enumerating every input of a particu-
lar patient) on retrospective administrative or clinical
data18 and gross costing on primarily collected data5.
The present study utilized a combination approach
for cost evaluation—individual direct costs based on
gross contract data (hospitalization and TDM), modi-
fied market price (outpatient), and micro-costing from
retrospective clinical data (AED); and cost of unem-
ployment based on average wages. Nevertheless, since
local epidemiological literature and statistical records
on illness-specific mortality and work-related indirect
costs relevant to epilepsy were not available, we had to
apply a United States model on the target population.
Approach in estimating indirect costs
We adopted a human capital approach in deriving
the indirect costs, which assumes that an individual’s
worth to the society is equivalent to his/her produc-
tive output valued at a discounted market price. When
a person’s earning capacity is impaired, resources of
the society have to be diverted towards supporting this
unproductive member. Therefore, epilepsy will result
in costs incurred by the society equivalent to, for the
case of mortality, the projected lifetime loss of earn-
ings of the deceased; and, for the case of morbidity,
the reduced income due to unemployment and under-
employment. Indirect costs are deduced by summing
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ual. However, techniques based on this approach will
under-estimate the indirect costs from individuals who
do not generate an income, such as students, house-
wives, and children22. To overcome this problem, a
unified value of lost productivity to calculate the op-
portunity costs of restricted activities for all patients
was applied. People will take the consequences or ben-
efits of their daily activities into account when allocat-
ing their time and energy, and choose to devote these
resources to activities that would result in the greatest
utility. Gains from activities other than working can
be considered as trade-offs of the incomes generated
by working, and opportunity costs of restricted activ-
ities from epilepsy was, therefore, assumed to value
equally as the corresponding level of lost productiv-
ity.
Intangible cost due to impaired quality of life from
epilepsy is increasingly recognized as an important
component of the burden of illness. Measurement of
disease-specific quality of life outcomes is now be-
ing recommended as an integral part of epilepsy re-
search as well as clinical practice23–25. The ICEE also
stressed the importance of humanitarian gains in ad-
dition to fiscal benefits in managing epilepsy2. The
present analysis did not allow for the estimation of
intangible cost because of its retrospective nature. A
prospective longitudinal study will be appropriate for
assessing its magnitude in the target population.
Consumption pattern in relation to disease
severity
Previous studies indicated that patients with MRE
utilize substantially more resources than those with
better seizure control3, 18. Our findings were similar,
which occurred during both the study and projected
periods. On analyzing the cost components, the re-
spective mean expenditures per person on AEDs and
outpatient visits in patients with MRE were almost
tripled and doubled during the study period. The mean
cost per person on AEDs for patients with interme-
diate seizure control was also doubled. The cost in-
crements were probably due to the introduction of
expensive AEDs and more frequent clinical monitor-
ing in these patients. Although there was no apparent
economic benefit during the study period, the long-
term changes in resource utilization are still uncertain.
Moreover, our model is inadequate for determining
the modification in indirect costs over both the study
and projected periods. Another remarkable finding is
that the mean expenditure per person on AEDs was
almost tripled for those in early remission while that
of other items remained similar throughout the study
period. This is consistent with our changing prescrip-tion practice: sustained-release preparations of val-
proic acid and carbamazepine are preferred to pheny-
toin and phenobarbitone in treating newly diagnosed
patients.
When compared with the figures from other cost-
of-illness studies26, our estimates for the cost per pa-
tient were much lower. Several factors might explain
this discrepancy. The preferable use of generic for-
mulations over brand-name AEDs, a strict policy for
TDM, and possibly the relatively late introduction of
adjunctive AEDs in our clinic might have lowered the
direct costs. Moreover, our study design did not in-
clude the costs of epilepsy surgery and pre-surgical
evaluations. The use of gross costing in valuing hospi-
talization might under-estimate the actual expenditure
in some patients, for example those receiving inten-
sive care for status epilepticus or major trauma from
seizures. For the indirect costs, our method did not al-
low for the estimation of mortality-related lost produc-
tivity during the study period. In addition, there was
no well-structured vocational policy for epileptic pa-
tients in Hong Kong so that their employability might
be worse than their United States counterparts, and
our model might under-estimate their unemployment
rate.
Indirect costs of epilepsy
It is notable that indirect costs accounted for the ma-
jority of the total costs—an observation that was also
demonstrated in other studies3–6, 27. The ratio of in-
direct to direct costs and the rate of increment of indi-
rect costs were particularly high for patients with MRE
and intermediate seizure control. Mean indirect costs
per person for those with either MRE or intermediate
seizure control were doubled in 1996 when compared
with 1992. Sensitivity analyses indicated that unem-
ployment rate and annual discount rate were parame-
ters that would exert the most leverage on the future
projected costs. These factors are dependent on the
overall economy of the society and psychosocial func-
tions of epileptic patients. There are two important im-
plications of these findings.
Firstly, the recent financial crisis in Southeast Asia,
which also affects Hong Kong profoundly, has resulted
in an unfavourable economic and investment environ-
ment. Discount rate is determined by the stability of
economic growth. It is foreseeable that returns on cap-
ital investments will be reduced in the coming few
years so that the annual discount rate will be lowered
or even be negative. Moreover, the unemployment rate
of Hong Kong by the end of 1998 was 5.7%, which
had already exceeded the sensitivity range applied in
the analysis. In view of the adverse economic factors, a
substantial increase in the indirect costs from epilepsy
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S28.APPENDIX 1: METHOD FOR PREDICTING
THE LONG-TERM OUTCOME IN GROUP 1
PATIENTS
One thousand seven hundred and eighty-nine pa-
tients who were in remission for at least 2 years on
AEDs were recruited to the Medical Research Council
Antiepileptic Drug Withdrawal Study11. One thousand
and thirteen of them were randomized with 510 pa-
tients allocated to the slow withdrawal group. Ten of
them decided not to discontinue AEDs and another
eight resumed AEDs despite being seizure free after
withdrawal. By the end of 4.5 years, 373 patients were
in remission without AEDs. Therefore, for those in
whom withdrawal was attempted, 76% (373÷ (510−
18)) remained seizure free at the end of the follow-up
period. If all the 1013 patients were subjected to AED
withdrawal, 977 patients (1013 × (510 − 18) ÷ 510)
would agree to comply. Among these patients, it is es-
timated that 741 (977× 373÷ (510 − 18)) were able
to discontinue AEDs and remain in remission, which
was 41% of the overall 1789 patients.
The chance of achieving remission without AEDs
becomes smaller in those with a longer history of
epilepsy and duration of AED treatment. The addi-
tional percentage of patients that can stop AEDs suc-
cessfully per year will level off at around 5 years af-
ter commencing AED withdrawal. We assume that pa-
tients who remain seizure free for 2 years but cannot
be or opt not to be taken off AEDs over the next 5
years will require long-term drug therapy. Fifty-nine
percent of patients belong to this group, including 45%
([776+ (1013× 18÷ 510)]÷ (1013+ 776)) in whom
AED withdrawal is not attempted on the patients’ or
physicians’ discretion, and 14% in whom AED dis-
continuation fails. For ease of calculation, we assume
AEDs can be withdrawn from an equal number of pa-
tients from year three to year seven so that eventually
59% of patients will require long-term AEDs. There-
fore, by the end of year three to year seven after onset,
the expected probability to remain on treatment for a
Group 1 patient will be 91%, 84%, 75%, 67%, and
59%, respectively. Afterwards, he or she will be cat-
egorized as a Group 2 patient.
